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Abstract  19 
Background 20 
Anti-TNF exposure has been linked to demyelination events. We sought to describe the clinical 21 
features of demyelination events following anti-TNF treatment and test whether affected patients 22 
were genetically predisposed to multiple sclerosis (MS). 23 
Methods 24 
We conducted a case-control study to describe the clinical features of demyelination events 25 
following anti-TNF. We compared genetic risk scores (GRS), calculated using carriage of 43 26 
susceptibility loci for MS, in 48 cases to 1219 patients exposed to anti-TNF who did not develop 27 
demyelination.    28 
Results  29 
Overall, 39 (74%) cases were female. The median age (range) of patients at time of demyelination 30 
was 41.5 years (20.7 – 63.2). The median duration of anti-TNF treatment was 21.3 months (0.5 - 31 
99.4) and 19 (36%) patients were receiving concomitant immunomodulators. Most patients had 32 
central demyelination affecting the brain, spinal cord or both. Complete recovery was reported in 12 33 
(23%) patients after a median time of 6.8 months (0.1 – 28.7). After 33.0 months of follow-up partial 34 
recovery was observed in 29 (55%) patients, relapsing and remitting episodes in 9 (17%), progressive 35 
symptoms in 3 (6%): 2 (4%) patients were diagnosed with MS. There was no significant difference 36 
between MS GRS scores in cases (mean -3.5 x 10-4, SD 0.0039) and controls (mean -1.1×10-3, SD 37 
0.0042) (p=0.23). 38 
Conclusions 39 
Patients who experienced demyelination events following anti-TNF were more likely female, less 40 






controls who did not. Large prospective studies with pre-treatment neuroimaging are required to 42 







Anti-TNF therapies were licensed for use in 1998 and have revolutionised the management of a 45 
range of immune mediated inflammatory disorders.  Case reports linking infliximab and etanercept 46 
to demyelination events followed and prompted the Food and Drug Administration and the 47 
European Medicines Agency to issue safety warnings1–3. Contemporaneously, a randomised 48 
controlled trial of lenercept (a recombinant TNF receptor p55 immunoglobulin fusion protein) in 49 
patients with multiple sclerosis was discontinued early, because of the increased frequency of early 50 
and more severe demyelination exacerbations in the treatment compared with placebo arms 4.    51 
Demyelinating events have been reported with all licensed anti-TNF therapies in the treatment of 52 
patients with inflammatory bowel disease(IBD)5, rheumatoid arthritis6 and psoriasis7. Because 53 
demyelination was rare in the respective registration trials it is not possible to conclude whether a 54 
causal association exists between anti-TNF therapies and demyelination events7,8. Data from post-55 
marketing adverse event registries seem to be reassuring, citing similar rates of demyelination to the 56 
background risk of multiple sclerosis9. However, these data are likely to underestimate rates of anti-57 
TNF related demyelination because of confounding by voluntary reporting. In support of this 58 
assertion, data from a Danish population based-cohort study of patients with IBD treated with at 59 
least one anti-TNF reported a two-fold relative risk of demyelinating events10. Moreover, because 60 
demyelination can be clinically silent the actual risk attributable to anti-TNF therapies maybe even 61 
higher. Evidence of demyelination was reported in 4% of patients with rheumatoid arthritis or 62 
spondyloarthopathies treated with anti-TNF therapies after 18 months in whom pre-treatment MRI 63 
imaging was normal 11.          64 
Considerable uncertainty remains, therefore, as to whether anti-TNF exposure induces 65 
demyelination in patients genetically pre-disposed to multiple sclerosis or is a chance observation 66 






because symptomatic demyelination events following anti-TNF are uncommon their natural history 68 
is poorly defined.  69 







Study design and setting 72 
We conducted a retrospective case-control study to report the clinical features and natural history 73 
of demyelination events following anti-TNF therapy. We sought to assess whether demyelination 74 
events occurred in patients at increased genetic risk for multiple sclerosis.   75 
Study populations  76 
Potential cases were recruited from 41 UK and six international sites between 2012 and 2018. 77 
Patients were identified through: opportunistic clinical encounters, cases reported to the British 78 
Neurological Surveillance Unit (BNSU) or to the Medicine and Healthcare Products Regulatory 79 
Authority Yellow Card  scheme. 80 
Inclusion criteria were all of the following: exposure to anti-TNF drug(s) without a preceding history 81 
of neurological symptoms suggestive of demyelination; neurological symptoms persisting for at least 82 
24 hours following anti-TNF exposure; MRI brain and/or spinal cord imaging and/or or 83 
electrophysiological studies (nerve conduction or evoked potentials) consistent with central nervous 84 
system (CNS) or peripheral nervous system (PNS) disease, respectively; and neurological opinion 85 
implicating the anti-TNF drug as a cause of demyelination necessitating drug withdrawal if the 86 
patient was still receiving the drug. 87 
Investigators at each site completed a custom-designed case report form (Supplemental Appendix 88 
3), that captured the following data: patient demographics (age, weight, height, ethnicity, smoking 89 
and inflammatory disease history); drug exposure data (anti-TNF, anti-TNF dose, drug start date, 90 
drug stop date) and demyelination history (onset, duration, resolution, investigations and 91 






Case report forms and supporting imaging and/or electrophysiological tests were reviewed 93 
independently by a panel including a neuro-radiologist and at least 2 neurologists. Consistent with 94 
our prior pharmacogenetic studies12–14 we modified the Liverpool Adverse Drug Reaction Causality 95 
Assessment Tool to verify cases (Supplemental Figure 1). “Possible” cases were defined as patients 96 
who had equivocal investigations or clinical features of demyelination. “Probable” cases 97 
demonstrated clinical, radiological and / or electrophysiological features of demyelination with a 98 
clear temporal relationship with anti-TNF therapy and no other cause for demyelination. In addition 99 
to these criteria, “definite” cases were individuals who had a recurrence of demyelination on anti-100 
TNF therapy rechallenge. Cases assigned as “unlikely” were excluded. Definite, probable and 101 
possible cases were included in subsequent analyses. We classified patients according to whether 102 
they had central (brain and/or spinal cord) or peripheral nervous system involvement and whether 103 
their illness was a clinically isolated syndrome or had a relapsing phenotype.  Clinically isolated 104 
syndrome was defined as a first episode of neurological symptom lasting for 24 hours and is caused 105 
by inflammation or demyelination in the central nervous system. Partial recovery was defined as an 106 
episode of demyelination with partial or no resolution of symptoms at the time of follow-up. 107 
Patients recruited to the Personalising Anti-TNF Therapy in Crohn’s disease (PANTS) study without a 108 
history of demyelination were used as controls. In brief, the PANTS study is a UK-wide, multicenter, 109 
prospective observational cohort study of 1610 patients with Crohn’s disease treated with infliximab 110 
(originator, Remicade [Merck Sharp & Dohme, UK] and biosimilar, CT-P13 [Celltrion, South Korea]), 111 
and adalimumab (Humira [Abbvie, USA])15. To allow us to identify phenotypic factors associated with 112 
demyelination following anti-TNF therapy, each IBD case was matched to five anti-TNF exposed 113 
controls from the PANTS cohort by duration of anti-TNF therapy. Genetic risk scores for multiple 114 
sclerosis in all cases were compared to scores from control patients without neurological adverse 115 
events included in the genetics arm of the PANTS study.  116 






DNA was extracted from whole blood and genotyped using the Infinium Global Screening (cases) and 118 
Illumina CoreExome microarrays (controls). Individuals of non-European ancestry were identified 119 
using principal component analyses and excluded. Checks were made for relatedness using KING 120 
1.916.  121 
Variants with a genotype call rate of <95%, a minor allele frequency of less than 1% or with 122 
significant evidence of deviation from Hardy-Weinberg equilibrium (p <1×10-6) were excluded. We 123 
corrected for batch-effect by removing variants with an uncorrected p-value of < 0.05 for association 124 
with batch using Fisher’s exact test. Palindromic variants were also removed prior to imputation 125 
leaving 130,132 genotyped variants. Single nucleotide polymorphisms were imputed using the 126 
Sanger Imputation Service to the Haplotype Reference Consortium (HRC) panel and a post-127 
imputation information score of 0.9 was used as a cut-off. We constructed a multiple sclerosis 128 
genetic risk score (GRS) using data from previously identified risk variants17. Genetic risk scores were 129 
generated by summing the carriage status at each locus multiplied by the log odds ratio of that 130 
variant18,19.  Susceptibility loci included in our GRS were defined as risk variants with a p-value < 5 x 131 
10-6 and no closer in the genome than within 1 mega-base of another risk variant with a lower p-132 
value. Overall, 51 loci were identified, details of their odds ratios and relative weightings are given in 133 
Supplemental Table 1. 134 
We validated our GRS using subjects with multiple sclerosis identified in the UK Biobank, a study of 135 
over 500,000 individuals aged between 37 and 73 years recruited between 2006 and 201020. 136 
Multiple sclerosis cases were defined in the UK Biobank using either the International Classification 137 
of Diseases (ICD) 10 code G35, ICD9 code 340, or self-report code 1261. Those with other 138 
demyelinating conditions, defined by an ICD10 code of G36 / G37, ICD9 code of 341, or self-report 139 
code of 1397, were excluded. We validated the GRS in unrelated Europeans only. European ancestry 140 






Kinship16. Imputation was performed by the UK Biobank21. The dataset used for validation of the GRS 142 
contains 1680 multiple sclerosis cases and 387,932 controls. 143 
Statistical methods 144 
Pseudonymised data were managed using purpose designed electronic data capture tools at the 145 
Royal Devon and Exeter NHS Trust. Statistical analyses were undertaken in R 3.6.1 (R Foundation for 146 
Statistical Computing, Vienna, Austria), PLINK version 1.90b3.42 and MATLAB version R2017a. All 147 
analyses were two tailed and p-values <0.05 were considered significant.  148 
Descriptive statistics were reported, based on normality, as mean (SEM) and median [IQR] for 149 
continuous data and as proportions for categorical data unless otherwise stated. We included 150 
patients with missing clinical data in analyses for which they had data and specified the denominator 151 
for each variable. Propensity matching of IBD cases to PANTS controls on duration of anti-TNF drug 152 
exposure was undertaken using the MatchIt package in R22. We performed univariable analyses, 153 
using Fisher’s exact test for categorical data and Mann-Whitney U tests for continuous data, to 154 
identify clinical variables associated with demyelination events in cases versus controls.  155 
We tested for differences in multiple sclerosis genetic risk scores between cases and controls both in 156 
the UK Biobank and in our case-control study of patients exposed to anti-TNF, using Student’s t-157 
tests. Diagnostic performance of these scores was assessed using receiver operating characteristics 158 
(ROC) analyses.  Fisher’s exact test with Bonferroni correction was used to test association at each 159 
locus.    160 
Ethical considerations 161 
The protocol was approved by the National Research Ethics Committee (11/SW/0222, Exeter 162 
pharmacogenetic PRED4 programme), and international sites sought local ethical approval 163 
respectively. All participants involved provided informed written consent. Development and 164 







Study overview  167 
Case disposition through the study is shown in Figure 1. Between 2012 and 2018, 66 patients were 168 
recruited from 41 UK and 6 international sites. Following adjudication, we excluded 13 (20%) 169 
patients: 7 (11%) in whom review of investigations refuted evidence of demyelination or a temporal 170 
relationship with anti-TNF exposure; and 6 (9%) in whom an alternative diagnosis was more likely 171 
(mycoplasma infection, hypertension, vitamin B12 deficiency, mononeuritis multiplex, multifocal 172 
acquired demyelinating sensory and motor neuropathy and myositis).  Only one patient was re-173 
challenged with an anti-TNF drug after a demyelination event.  174 
Control subject disposition through the study is shown in Figure 1. Overall, 2% (34/1610) patients 175 
suffered a neurological adverse event during follow-up in the PANTS study and were excluded from 176 
this control cohort. The adverse event was attributed to the anti-TNF drug in 24/34 patients, leading 177 
to drug withdrawal in half; however, following neurological assessment none were diagnosed with 178 
demyelination. 179 
After assessment using genetic quality control methods, we excluded 5 cases: 3 (6%) for non-white 180 
European ethnicity and 2 (4%) for failure of genotyping. We did not identify relatives of third degree 181 
or closer.  182 
Clinical characteristics   183 
The clinical features of verified cases are summarised in Table 1. Overall, 39 (74%) patients were 184 
female and 44 (83%) patients were white European. The median age (range) was 41.5 years (20.7 – 185 
63.2). Thirteen (25%) were current and 13 (25%) were ex-smokers. The indication for anti-TNF 186 
therapy was IBD in 32 (60%), rheumatoid arthritis in 12 (23%), psoriasis or psoriatic arthropathy in 7 187 
(13%), and ankylosing spondylitis in 5 (9%) patients, respectively. Three patients received anti-TNF 188 






25 (47%), adalimumab in 19 (36%), etanercept in 7 (13%), golimumab in 1 (2%) and certolizumab in 1 190 
(2%) patient(s), respectively. Concomitant immunomodulator use was observed in 19 (36%) cases, 191 
(thiopurine 8 (42%), methotrexate 8 (42%), ciclosporin 2 (11%), leflunomide 1 (5%)). Overall, the 192 
median (range) duration of anti-TNF treatment prior to demyelination event was 21.3 [0.5-99.4] 193 
months. 194 
Propensity matching in the subset of patients with IBD resulted in a median [IQR] duration of anti-195 
TNF treatment prior to demyelination event of 9.9 [5.1 - 31.9] and 9.9 [5.1 - 25.2] months in cases 196 
and controls, respectively (p= 0.44). Cases were more likely to be female (84% [27/32] vs 58% 197 
[92/160], respectively, p = 0.008, Table 2) and were less likely to have been treated with a 198 
concomitant immunomodulator (immunomodulator 31% [10/32] vs 56% [89/160] respectively, p = 199 
0.02). No differences were seen according to age, ethnicity, body mass index (BMI) or cigarette 200 
smoking. 201 
Natural history of demyelination  202 
Five (9%) patients had a family history of multiple sclerosis, although none were first degree 203 
relatives of a patient with multiple sclerosis. Four (8%) patients had MRI of the brain or spinal cord 204 
before the index demyelinating event. Three MRI scans were conducted prior to drug 205 
commencement and between 12.0 – 108.0 months before the demyelinating event. The indications 206 
were paraesthesia, seizures and an independent research study. Excluding the research MRI scan, 207 
none showed evidence of demyelination. The most common presentation was of central 208 
demyelination, observed in 44/53 (83%) patients. 31/44 (70%) patients with central demyelination 209 
had features in keeping with a clinically isolated syndrome (CIS). Of these 13/31 (42%) patients were 210 
noted to have a single lesion on MRI, and the remaining 18 (58%) multifocal lesions. Both cerebral 211 






The anti-TNF drug was withdrawn in all patients. In 24 (45%) patients no additional treatment was 213 
used, 21 (40%) patients received corticosteroids, 8 (15%) were treated with intravenous 214 
immunoglobulin and 4 (8%) patient received plasma exchange (Table 3). One patient who was re-215 
treated with an anti-TNF developed symptoms of demyelination after each of two re-challenges. The 216 
median (range) duration of follow-up after the index demyelination event was 31.0 months (2.0 – 217 
171.0); only 5/53 (9%) patients had less than six months of follow-up. Complete recovery was 218 
reported in 12 (23%) patients after a median (range) time of 6.8 months (0.1 – 28.7), partial recovery 219 
in 29 (55%) patients after a median (range) time of 33.0 months (2.0 – 118.0) of follow up. Relapsing 220 
and remitting episodes were observed in 9 (17%) patients, and 3 (6%) patients experienced 221 
progressive symptoms; all patients with relapsing and remitting episodes or progressive symptoms 222 
had central demyelination. Overall, 2 (4%) patients were subsequently diagnosed with multiple 223 
sclerosis. 224 
Genetic Analysis  225 
After genetic imputation, we excluded 8 of the 51 target loci from the genetic risk score analyses: 6 226 
loci because of poor imputation (INFO score <0.9) and 2 loci because they were not included in the 227 
HRC reference panel.  The 43 loci that were used to construct our multiple sclerosis GRS are shown 228 
in Supplementary Table 1. We used this multiple sclerosis GRS in the UK Biobank and observed a 229 
significant difference between multiple sclerosis cases and controls (p = 3.2 x 10-116) (Figure 3) with 230 
an area under the curve (95% CI) of 0.65 (0.64 – 0.66) (Figure 4).  231 
There was no significant difference in multiple sclerosis GRS scores between cases and controls 232 
(cases [mean -3.5 x 10-4, SD 0.0039] vs. controls [mean –1.1×10-3, SD 0.0042], p=0.23) (Figure 5). 233 
Moreover, no significant associations with demyelination were seen at any individual locus 234 
(Supplementary Table 2). We did not observe genomic inflation for the SNPs used in our GRS 235 
(Supplementary Figure 2). The AUC (95% CI) for predicting anti-TNF related demyelination in our 236 






Discussion  238 
Key results  239 
Anti-TNF exposed patients who suffered demyelination events were more likely to be female and 240 
less frequently treated with an immunomodulator. Patients who developed demyelination events 241 
had similar genetic risk scores for multiple sclerosis to control patients who did not develop 242 
demyelination events after anti-TNF therapy. Following almost three years of follow-up, about half 243 
of our demyelination cases had received one or more treatments for demyelination and three-244 
quarters had ongoing neurological symptoms.     245 
Interpretation 246 
Shared genetic susceptibility between autoimmune and inflammatory conditions may account for 247 
the increased risk of multiple sclerosis reported in patients with rheumatoid arthritis and IBD23,24. 248 
Previous genetic studies of anti-TNF induced demyelination are limited to a negative candidate gene 249 
study of TNFRSF1A in patients with rheumatoid arthritis25. Here, we have shown that anti-TNF 250 
treated patients who developed demyelination events had overlapping genetic risk scores for 251 
multiple sclerosis with anti-TNF exposed controls who did not develop demyelination. It is unlikely, 252 
then, that anti-TNF therapies lead to demyelination only in individuals genetically pre-disposed to 253 
multiple sclerosis. In support of this assertion only two cases in our study were subsequently 254 
diagnosed with multiple sclerosis.      255 
 256 
There was a female predominance amongst patients with demyelination following treatment with 257 
anti-TNF therapies. We did not observe any other classical risk factors for multiple sclerosis arguing 258 
against the hypothesis that these events represent the chance development of de novo multiple 259 
sclerosis. For example, compared to previously reported case series of patients with multiple 260 






degree relative with multiple sclerosis 28 . In support of anti-TNF related demyelination being an 262 
adverse drug reaction, we observed rapid recurrence of neurological symptoms in the one individual 263 
who was re-challenged with an anti-TNF drug after a demyelination event.   264 
 265 
Limitations and generalisability 266 
Our study has several strengths including rigorous cross-disciplinary independent case verification, 267 
and for the first time we explored the value of a multiple sclerosis GRS in a study of anti-TNF related 268 
demyelination. We acknowledge, however, the following important limitations: first, in keeping with 269 
all case-control studies our data are susceptible to recall bias, with greater recruitment of more 270 
severe cases. Second, because this was a convenience sample, we were unable to report the 271 
incidence of demyelination events. However, in our prospectively collected control cohort of 1610 272 
patients, 2% reported neurological symptoms during follow-up although none were confirmed as 273 
being due to demyelination. Third, our retrospective data collection from medical records is subject 274 
to missingness and interpretation bias. In particular, we have no data relating to other important 275 
environmental risk factors for multiple sclerosis including vitamin D deficiency and previous Epstein-276 
Barr virus infection. Fourth, our genetic analyses were limited to patients of white European 277 
ancestry and only patients with Crohn’s disease made up the control cohort, which limits the 278 
generalisability of our findings. Finally, despite the study being open for six years we accept that our 279 
sample size was too small to permit a pharmacogenetic genome wide association study to identify 280 
novel variants associated with demyelination following treatment with anti-TNF and we were also 281 
underpowered to detect a difference in our cases and multiple sclerosis cases from the UK Biobank.  282 






Conclusion   284 
This large case-control study adds comprehensive clinical information to the existing reports of 285 
demyelinating events associated with anti-TNF therapy for inflammatory disorders. Demyelination 286 
events were no more common in patients at genetic risk for multiple sclerosis. Further 287 
pharmacogenetic studies with prospective neuroimaging are required to define the risk of 288 
demyelination following anti-TNF therapy and to identify genetic susceptibility loci.  289 
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Figures and Tables  401 
Figure 1. Flow diagram and Study Overview of Case and Control Cohorts 402 
 403 
* Three patients received anti-TNF therapy for more than one indication 404 
Abbreviations: IBD = Inflammatory Bowel Disease, PANTS = Personalised Anti-TNF Therapy in Crohn’s 405 
disease, MedDRA = Medical Dictionary for Regulatory Activities, RA = Rheumatoid Arthritis, AS = 406 






Figure 2. Pattern of anti-TNF related demyelination in 53 cases 408 






Figure 3. Probability distribution of genetic risk scores (GRS) in patients with multiple sclerosis in 410 
the UK Biobank 411 






Figure 4. Receiver operating characteristic (ROC) curves of multiple sclerosis (MS) genetic risk 413 
scores (GRS) in MS patients in the UK Biobank and anti-TNF related demyelination cases 414 






Figure 5. Probability distribution of genetic risk scores (GRS) in cases and controls 416 
417 






Table 1. Baseline demographic of cases with demyelination related to anti-TNF therapy 419 
Characteristic Cases 
Patients, n 53 
Gender 
Female 39 (74%) 
Male 14 (26%) 
Age 
Mean (SD) 40.6 (10.5) 
Median [Min, Max] 41.5 [20.7, 63.2] 
Ethnicity 
White European 44 (83%) 
Other white background 4 (8%) 
Mixed white and asian 2 (4%) 
Any other Asian 2 (4%) 
Carribean 1 (2%) 
BMI 
Median [Min, Max] 24.9 [18.0, 43.2] 
Missing 5 (9%) 
Condition 
IBD 32 (60%) 
RA 12 (23%) 
Psoriasis 7 (13%) 
AS 5 (9%) 
Drug 
Infliximab 25 (47%) 
Adalimumab 19 (36%) 
Etanercept 7 (13%) 
Certrolizumab 1 (2%) 
Golimumab 1 (2%) 
Family History 
Yes 5 (9%) 
No 42 (79%) 
Smoking 
Current 13 (25%) 
Ex 13 (25%) 
Never 21 (40%) 
Immunomodulator 
Yes 19 (36%) 
No 34 (64%) 
Duration on anti-TNF (months) 






BMI, body mass index; IBD, inflammatory bowel disease; RA, rheumatoid arthritis; AS, ankylosing 420 






Table 2. Characteristics of anti-TNF exposed inflammatory bowel disease cases and controls 422 
Characteristic (IBD patients) Case  
n = 32 
Control 
n = 160 
p value 
Sex 
Female 27 (85%) 92 (58%) 
0.008 
Male 5 (16%) 68 (43%) 
Age (median [IQR]) 34.1 [29.5 - 46.5] 33.9 [25.0 - 48.0] 0.542 
BMI (median [IQR]) 23.6 [20.6 - 27.1] 24.1 [20.3 - 28.9] 0.539 
Smoking  
   Current 6 (22%) 27 (17%) 
0.75    Ex 9 (33%) 50 (32%) 
   Never 12 (44%) 81 (51%) 
Concurrent immunomodulator 10 (31%) 89 (56%) 0.02 






Table 3. Clinical characteristics of demyelination events in anti-TNF exposed cases 424 
Characteristic of demyelination events Cases (n = 53) 
Investigations  
Lumbar puncture  32 (60%)  
Nerve conduction studies  8 (15%)  
Electrophysiology  19 (36%)  
Treatment  
Steroids  21 (40%)  
IVIG  8 (15%)  
Plasma exchange  4 (8%)  
None  24 (45%)  
Other  1 (2%)  
Time to recovery (Months)  
Median [Min, Max]  6.75 [0.10, 28.7]  
Duration of follow-up (Months)  
Median [Min, Max]  31.0 [2.00, 171]  
IVIG, intravenous immunoglobulin. 425 
